Cancer - Key Publications

1. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice L, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan S, Griffith M,Moradian A, Cheng S-WG, Morin G, Watson P, Gelmon K, Chia S, Chin S-F, Curtis CN, Rueda O, Pharoah P, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello J, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C*, Marra MA, and Aparicio S. Primary triple negative breast cancers exhibit a continuous spectrum of clonal and mutational evolution. Nature, 486: 395-399, 2012 [*co-senior/co-corresponding author].

2. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale A-L, Brenton JD, Tavare S, Caldas C*, and Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486: 346-352, 2012 [*co-senior/ co-corresponding author].

3. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE. The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man. Cancer Cell. 23(1):35-47, 2013.

4. Ong, Chin-Ann J., Shapiro, J., Nason, K.S., Davison, J.M., Liu, X., Ross-Innes, C., O'Donovan, M., Dinjens, W.N.M., Biermann, K., Shannon, N., Worster, S., Schulz, L.K.E., Luketich, J.D., Wijnhoven, B.P.L., Hardwick, R.H. and Fitzgerald, R.C. on behalf of the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. A three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. Journal of Clinical Oncology 2013; 31(12): 1576-82. Epub 2013.

5. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med, 368(13): 1199-1209. Epub 2013.

6. Fletcher MN, Castro MA, Wang X, de Santiago I, O’Reilly M, Chin SF, Rueda OM, Caldas C, Ponder BA, Markowetz F, Meyer KB. Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun, 4:2464, 2013.

7. Ruau D, Ng FS, Wilson NK, Hannah R, Diamanti E, Lombard P, Woodhouse S, Göttgens B. Building an ENCODE-style data compendium on a shoestring. Nature Methods 10(10):926, 2013.

8. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gunes G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorene I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara

S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du M’Q, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ton D, Vannucchi AM, Papaemmanuil E, Campbell PJ and Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med, 369(25): 2391-2405, 2013.

9. Aziz A*, Baxter EJ*, Edwards C, Ito M, Cheong CY, Bench A, Kelley R, Silb er Y, Beer PA, Chng K, Renfree MB, McEwen K, Gray D, Nangalia J, Mufti GJ, Helstrom-Linberg E, Kiladjian JJ, McMullin MF, Campbell PJ, Ferguson-Smith AC$, Green AR$. *Joint first autors, $joint last authors. Cooperativity of imprinted genes In-activated by acquired chromosome 20 deletions. Journal of Clinical Investigation, 123(5): 2169-2182, 2013.

10. Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias V, Shaw G, Sharma NL, Ross-Adams H, Scott H, Vowler SL, Howat WL, Warren AY, Wooster RF, Mills IG, Neal DE. Hes6 drives a critical AR transcriptional program to induce castration resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. In Press.